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L
ess than a decade ago, epidemiolog-
ical research classiﬁed high-fat dairy
products as integral to a “Western”
dietary pattern that was associated with
an increased risk for developing type 2
diabetes (1). Animal fat, including that
found in whole milk and high-fat dairy
products, was thought to be the patho-
genic factor with little consideration of
the composition of milk fat, which has
the potential opposite effects of various
fatty acids (saturated fatty acids, trans fatty
acids, and conjugated linoleic acid) (2).
ThestudybyFumeronetal.(3)inthis
issue of Diabetes Care found an inverse
relationship between intake of dairy
products and incident diabetes and sev-
eral cardiometabolic risk factors in the
French DESIR (Data from the Epidemio-
logical Study on the Insulin Resistance
Syndrome) study. A limitation of the
DESIR analysis is the homogeneity of
the French study population. Generaliz-
ingthestudyﬁndingtomorediversepop-
ulation groups, especially populations of
colorwithdisparateratesofdiabetes,may
not be appropriate. However, the DESIR
ﬁndings are consistent with a number of
recent epidemiological studies that have
also reported an inverse relationship be-
tween intake of dairy products or nu-
trients in dairy products and the risk of
developing obesity-related chronic dis-
eases including diabetes in a variety of
population groups (4–13).
Much of the early interest in dairy
intake focused on its mineral content in
relation to blood pressure. Although cal-
cium is the nutrient most often associated
with dairy products, a broader view of the
mineral content is needed. Dairy products
provide magnesium and potassium to the
dietary intake as well as calcium. Although
the effects of dairy products on the re-
duction in blood pressure may be related
to the balance of these minerals (11,14),
mineral supplementation trials found little
beneﬁt( 1 5 , 1 6 ) .
Trying to examine why dairy prod-
ucts may reduce diabetes risk is fraught
with difﬁculty. Examination of dairy in-
take in relation to obesity, diabetes, and
cardiometabolic risk requires consider-
ationofawiderangeofnutrients.Although
vitamin D has been postulated to reduce
diabetes risk and convey cardiometabolic
beneﬁt, the evidence base is weak (17).
Furthermore, the DESIR food frequency
questionnaire is not structured to provide
vitamin D values for exploration of the re-
lationship. For example, the role of dairy
protein also needs to be considered (18).
Trying to extrapolate from observational
data, in which dairy products are associ-
ated with lower risk, to food or nutrient
recommendations is extremely chal-
lenging.
Dairy products have long been in-
tegral to federal dietary recommenda-
tions, but current recommendations are
based on evidence from the Dietary
Approaches to Stop Hypertension (DASH)
study,whichevaluatedthebloodpressure
and other health outcomes of a dietary
pattern containing low-fat dairy foods
(three servings) (19). The DASH dietary
pattern is highlighted in the 2010 Dietary
Guidelines and has potential cardiometa-
bolic beneﬁts beyond reducing blood
pressure (20–22). A literature search
yielded no articles that examined the rel-
ative contribution of dairy products of the
DASH dietary pattern to the effects on
blood pressure or other cardiometabolic
risk factors.
Although the DASH dietary pattern
only contains low-fat dairy products, the
French DESIR and other epidemiological
studies suggest that intake of full fat as
wellas low-fatdairyproductsmay reduce
diabetesriskandprovidecardiometabolic
beneﬁts. These ﬁndings raise questions
about the role of fatty acids in dairy
products. Biomarkers related to dairy
intake as well as metabolic biomarkers
may provide insights to explain the
observational data.
Biomarkersrelatedtofattyacidintake
are of particular interest as research has
suggested that the tertiary structure and
shapeofsaturatedfattyacids(SFA)affects
their biological function (23). Exposure
of pancreatic b-cells to long-chain SFA
can affect their function by what has
been termed endoplasmic reticulum
(ER) stress, which can ultimately lead to
cell death. This process is thought to
play a role in the development of type 2
diabetes via a decrease in b-cell mass. Re-
search using a yeast-based model has ex-
amined many features of lipotoxicity in
human cells, to screen fatty acids of vari-
ous structures for their capacity to
counter ER stress. Findings from this re-
search suggest that the tendency of a fatty
acid to reduce SFA toxicity depends on a
complex conjunction of parameters, in-
cluding chain length, level of unsatu-
ration, position of the double-bonds, and
the nature of the isomers (cis or trans). As
building blocks for phospholipid synthe-
sis, fatty acids help regulate cell mem-
brane organization and ER function of
the b-cell.
Examination of the role of dairy prod-
ucts in obesity should consider the effects
of fatty acids in dairy products on insulin
resistance and diabetes-related risk. Rumi-
nant animals, such as cows, sheep and
goats synthesize both cis and trans isomers
forthemonounsaturatedfattyacidsoffatty
acids with chain lengths of 14 to 18 car-
bons. Trans-palmitoleic acid (also known
as trans-palmitoleate) is a 16 carbon trans
fatty acid found in the milk produced by
ruminant animals. Recently published re-
search has reported that higher levels of
circulating trans-palmitoleate were associ-
ated with lower levels of insulin resistance,
dyslipidemia, and incident diabetes in a
14-year follow-up of adults in the Cardio-
vascular Health Study (24).
Research suggesting that intake of
dairy products is associated with lower
risk of diabetes is intriguing. However, a
note of caution is needed to avoid jump-
ing on a treatment bandwagon based on
epidemiological data without evidence of
beneﬁt from well-controlled clinical trials
(25). When dietary patterns are associ-
ated with lower disease risk, the shortcut
approach for a quick ﬁx that focuses
on nutrient supplementation can be ill
advised.
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